Skip to content
PCVXVaxcyte, Inc.

Earnings

When Vaxcyte, Inc. reports, what it reported each quarter, and how the stock took the results.

31 quarters. Mar 31, 2019 to Sep 30, 2026. mixed units.

Next results · Q4 2026Projected

Feb 23, after the close

Tue, Feb 23, 2027in 97 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 22 – Mar 3

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Net income
-$246.51M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026-$297.06MNo Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, after the closeThe release5.8%by the close of Nov 5
    Revenue
    —
    —
    Net income
    -$297.06M
    N/M
    EPS
    -$1.99
    N/M
    On November 4, 2026, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.
  2. Q2 2026Aug 5, 2026, after the closeThe release+5.4%by the close of Aug 6
    Revenue
    —
    —
    Net income
    -$284.30M
    N/M
    EPS
    -$1.97
    N/M
  3. Q1 2026May 6, 2026, after the closeThe release9.9%by the close of May 7
    Revenue
    —
    —
    Net income
    -$320.62M
    N/M
    EPS
    -$2.30
    N/M
  4. Q4 2025Feb 24, 2026, after the closeThe release+2.4%by the close of Feb 25
    Revenue
    —
    —
    Net income
    -$246.51M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · after-hoursNov 4, 202635 d10-Q——-$1.995.8%
Q2 2026Jun 30, 2026Aug 5, 2026 · after-hoursAug 5, 202636 d10-Q——-$1.97+5.4%
Q1 2026Mar 31, 2026May 6, 2026 · after-hoursMay 6, 202636 d10-Q——-$2.309.9%
FY 2025
Q4 2025derivedDec 31, 2025Feb 24, 2026 · after-hoursFeb 24, 202655 d10-K———+2.4%
Q3 2025Sep 30, 2025Nov 4, 2025 · after-hoursNov 4, 202535 d10-Q——-$1.562.6%
Q2 2025Jun 30, 2025Aug 6, 2025 · after-hoursAug 6, 202537 d10-Q——-$1.229.1%
Q1 2025Mar 31, 2025May 7, 2025 · after-hoursMay 7, 202537 d10-Q——-$1.04+8.3%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · after-hoursFeb 25, 202556 d10-K———1.0%
Q3 2024Sep 30, 2024Nov 5, 2024 · after-hoursNov 5, 202436 d10-Q——-$0.833.3%
Q2 2024Jun 30, 2024Aug 6, 2024 · after-hoursAug 6, 202437 d10-Q——-$1.10—
Q1 2024Mar 31, 2024May 8, 2024 · after-hoursMay 8, 202438 d10-Q——-$0.85—
Earlier years, FY 2019 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026000054
10-QAug 5, 2026000043
10-QMay 6, 2026000017
10-KFeb 24, 2026000007
10-QNov 4, 2025000114
10-QAug 6, 2025000098
10-QMay 7, 2025000074
10-KFeb 25, 2025000028
10-QNov 5, 2024000097
10-QAug 6, 2024000052

Provenance

ProvenanceData status and checks

Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR